Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China

Xiao-Mei Huang1,2†, Bo-Fan Yang2†, Wen-Lin Zheng2,3, Qun Liu2, Fan Xiao2,3, Pei-Wen Ouyang1,2, Mei-Jun Li1,2, Xi-Yun Li4, Jing Meng1, Tian-Tian Zhang5, Yu-Hong Cui6,7 and Hong-Wei Pan1,2*

Abstract

Background: Diabetic retinopathy (DR) has become a leading cause of global blindness as a microvascular complication of diabetes. Regular screening of diabetic retinopathy is strongly recommended for people with diabetes so that timely treatment can be provided to reduce the incidence of visual impairment. However, DR screening is not well carried out due to lack of eye care facilities, especially in the rural areas of China. Artificial intelligence (AI) based DR screening has emerged as a novel strategy and show promising diagnostic performance in sensitivity and specificity, relieving the pressure of the shortage of facilities and ophthalmologists because of its quick and accurate diagnosis. In this study, we estimated the cost-effectiveness of AI screening for DR in rural China based on Markov model, providing evidence for extending use of AI screening for DR.

Methods: We estimated the cost-effectiveness of AI screening and compared it with ophthalmologist screening in which fundus images are evaluated by ophthalmologists. We developed a Markov model-based hybrid decision tree to analyze the costs, effectiveness and incremental cost-effectiveness ratio (ICER) of AI screening strategies relative to no screening strategies and ophthalmologist screening strategies (dominated) over 35 years (mean life expectancy of diabetes patients in rural China). The analysis was conducted from the health system perspective (included direct medical costs) and societal perspective (included medical and nonmedical costs). Effectiveness was analyzed with quality-adjusted life years (QALYs). The robustness of results was estimated by performing one-way sensitivity analysis and probabilistic analysis.

Results: From the health system perspective, AI screening and ophthalmologist screening had incremental costs of $180.19 and $215.05 but more quality-adjusted life years (QALYs) compared with no screening. AI screening had an ICER of $1,107.63. From the societal perspective which considers all direct and indirect costs, AI screening had an ICER of $10,347.12 compared with no screening, below the cost-effective threshold (1–3 times per capita GDP of Chinese in 2019).

Conclusions: Our analysis demonstrates that AI-based screening is more cost-effective compared with conventional ophthalmologist screening and holds great promise to be an alternative approach for DR screening in the rural area of China.

Keywords: Diabetic retinopathy, Screening, Artificial intelligence, Cost-effectiveness, Markov model

Background

Diabetic retinopathy (DR) is one of the most important microvascular complications of diabetes, which is difficult to be detected until irreversible damage or even blindness occurs [1–3]. DR was ranked fifth among the
major causes of global blindness [4]. The number of diabetic patients is projected to increase to 600 million by 2040, with one third expected to have diabetic retinopathy [5–7], presenting a huge medical and economic burden worldwide, especially in developing countries such as China. As reported by International Diabetes Federation diabetes atlas, there are 113.9 million adults with diabetes in China, which accounts for about 24% of all diabetic patients worldwide. Presently about half of the population, approximately 700 million people, are living in the rural areas of China, where the prevalence of diabetic retinopathy is higher than that of urban areas [8]. However, DR screening is not well performed in the rural areas of China due to unaffordability of medical cost, lack of medical facilities and limited access to conventional screening programs. Considering the importance of regular screening of people with diabetes for timely intervention and reduction of vision impairment [9], it is urgent to take measures to make DR screening more available and affordable in the rural areas of China. In this aspect, a new kind of screening strategy for DR incorporating artificial intelligence technology has great potential, especially in low- and middle-income countries [10].

Artificial intelligence (AI) using deep learning systems (DLS) emerges as a promising alternative approach in medical diagnosis of a variety of diseases, including diabetic retinopathy. It can provide instant DR diagnosis and reduce the burden of health system [11]. A DLS developed in Singapore has shown comparable diagnostic performance to human assessors and the savings to Singapore health system associated with switching the human assessment model to the semi-automated model are estimated to be $489,000, only 20% of the current annual screening cost [12, 13]. In India, an AI algorithm for DR and vision-threatening DR (VTDR) detection, using Remidio Fundus, produced a sensitivity of 96% and a specificity of 80% in detecting any diabetic retinopathy as well as a sensitivity of 99% and a specificity of 80% in detecting VTDR [14]. In China, the performance of a DLS model was evaluated for screening pre-proliferative diabetic retinopathy and diabetic macular edema, and the results showed a sensitivity of 97% and a specificity of 91% based on 19,900 images [14]. It has been found feasible to carry out AI based screening for DR in community hospitals [15]. As the study conducted in Xinjiang, China showed, AI had the same specificity (100%) and higher sensitivity (100% vs 79.1%) for referral DR screening, compared with manual screening [16]. It has been shown AI had relatively good consistency with ophthalmologist in DR grading, high specificity and acceptable sensitivity for the diagnosis of referral DR and any DR in community of China [17]. In Spain, AI system showed acceptable sensitivity (100% for referral DR and VTDR) and specificity (81.82% for referral DR and 94.64% for VTDR) against manual grading as well [18]. Compared with the conventional screening programs, AI screening can address several barriers including availability of human assessors, long-term financial sustainability and the growing need for DR screening and monitoring [13, 19].

To date, good diagnostic consistency in DR has been demonstrated between AI and manual grading. But little is known about the cost-effectiveness for AI based DR screening in rural China or other countries [20]. In order to provide economic evidence for medical and healthcare decision making, we assessed the cost-effectiveness of AI screening for DR relative to the conventional screening strategies using a Markov model, from the health system and societal perspectives.

Methods

Study Setting and description

The study was set in rural China. We conducted the analysis with a hypothetic cohort of 1000 patients in rural China. All patients were newly diagnosed with diabetes but without diabetic retinopathy, whose mean starting age was 44 years, representing the actual age distribution of patients with diabetes in rural China [21]. They were allowed to enter in one of the three screening groups: no screening group (the baseline group), AI screening group or ophthalmologist screening group, which meant they would take the DR screening and follow-up examinations later in the corresponding way. It was simulated in 35 yearly cycles. Rural China is defined as an area inhabited mainly by agricultural population engaged in agricultural production in China. According to the "Regulations for the Compilation of Statistical Division Codes and Urban–Rural Division Codes" formulated by the National Bureau of Statistics, the urban–rural division code is used to confirm whether the area is urban or rural (available at http://www.stats.gov.cn/tjsj/tjzj/tjyqhdmhcxhfxdm/). The urban–rural division code starting with 1 indicates that it is urban while the code starting with 2 indicates that it is rural. The ophthalmologists, the staff and the patients in DR screening, were aware of the research program and we have given their written informed consent. For conventional screening of DR in rural areas, medical teams with facilities and computational resources would go to the community health service stations in rural areas and perform screening. The medical staff would complete fundus images capture and visual acuity tests. The Ophthalmologists then would grade the fundus images combined with the results of the vision examination. Patients identified with vision-threatening DR
(VTDR), including severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), would be referred to superior hospitals to get laser treatment. Those identified with no diabetic retinopathy (NO DR) and mild diabetic retinopathy (Mild DR) would be recalled for a follow-up examination every year in superior hospitals while those with moderate diabetic retinopathy (Moderate DR) would be recalled for a follow-up examination every half year in superior hospitals. All of the follow-up examination’s results would be graded by ophthalmologists. The follow-up examinations included taking fundus images, performing a screening visual acuity exam, an intraocular pressure examination and a slit lamp microscope examination [22]. For AI screening, medical teams with facilities and computational resources would go to the community health service stations in rural areas and perform screening as well. An AI-based software would be used to grade fundus images instead of ophthalmologists. After the fundus images are obtained and vision examinations are performed, the AI-based software would be applied to grade the fundus images quickly and accurately, as well as giving management advice. The recommendations for patients in different DR progressions would be the same as ophthalmologist screening. What is different is that all the results of the follow-up examinations would be graded by the AI-based software. The AI-based software had very similar sensitivity and

![Markov Model structure](image)

**Fig. 1** Markov Model structure. DR=diabetic retinopathy; VTDR=vision-threatening diabetic retinopathy

| Table 1 | Markov Model Parameter Estimates and Assumptions |
|---------|---------------------------------|
| **Parameter** | **Value** | **Sensitivity Analysis Range** |
| 1. DR transition probabilities | | |
| No to Mild [27] | 0.07 | 0.01–0.10 |
| Mild to Moderate [27] | 0.19 | 0.166–0.214 |
| Moderate to VTDR [27] | 0.17 | 0.147–0.193 |
| VTDR to Stable [28] | 0.90 | 0.881–0.919 |
| Stable to Blindness [29] | 0.02 | 0.002–0.03 |
| VTDR to Blindness [29] | 0.09 | 0.07–0.11 |
| 2. Utility | | |
| No DR [30] | 0.94 | 0.83–1.05 |
| Mild DR [30] | 0.87 | 0.73–1.01 |
| Moderate DR [30] | 0.87 | 0.73–1.01 |
| VTDR [30] | 0.83 | 0.74–0.92 |
| Stable DR [31] | 0.85 | 0.72–0.78 |
| Blindness [30] | 0.81 | 0.73–0.89 |
| 3. Disutility of DR [32] | 0.066 | - |
| 4. Mortality multipliers [26] | | |
| Blindness | 2.34 | 2.22–2.46 |
| Diabetes | 1.90 | 1.04–2.7 |
| 5. Sensitivity, % | | |
| AI Screening screening [23] | 90.79 | 86.40–94.10 |
| Ophthalmologist screening [24] | 96.00 | 94.79–97.21 |
| 6. Specificity, % | | |
| AI screening [23] | 98.50 | 97.80–99.00 |
| Ophthalmologist screening [24] | 94.67 | 94.57–97.43 |
| 7. Compliance of screening [33], % | 86.00 | - |

DR Diabetic retinopathy, VTDR Vision-threatening diabetic retinopathy
specificity to ophthalmologists but with less cost and time for grading [23, 24].

Model design
We developed a hybrid decision tree based on Markov model to analyze the costs, effectiveness of each screening strategy. We also calculated the incremental cost-effectiveness ratio (ICER) of AI screening strategies relative to no screening strategies over 35 years. The model was developed with Treeage pro 2021 (TreeAge Software Inc, Williamstown, MA, USA), running for 35 cycles according to the mean life expectancy of patients diagnosed with diabetes in rural China [21].

The model simulated the progression of DR after being diagnosed with diabetes. The Markov model for diabetic retinopathy was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria [25], in which the patients were classified into seven health states: No DR, Mild DR, Moderate DR, VTDR, Stable DR, Blindness and death. In each cycle (every single year), the transition allowed between health states was as follows: No DR may remain or progress to mild DR. Mild DR may remain or progress to moderate DR. The Moderate DR may remain or progress to VTDR. Patients diagnosed with VTDR needed to receive laser treatment. If the treatment succeeded, the health state would stay at Stable DR, which was recalled for a follow-up examination every year. If failed, it would stay VTDR, which might progress to blindness. Meanwhile, Stable DR may remain or progress to blindness as well. People with all health states were likely to die, which was related to their age instead of DR progression. The Markov model structure was shown in Fig. 1.

Model inputs
Utility values (effectiveness) and transition probabilities were derived from literature. Mortality risks were calculated by multiplying the age-specific mortality risks by the mortality multipliers for diabetes and blindness, using linear interpolation. The natural age specific rates of mortality were derived from Chinese researchers [26]. Grading accuracy (sensitivity and specificity) of the two screening strategies was obtained from two published papers [23, 24], as shown in Table 1. Primary data was collected on the costs of ophthalmologist screening, AI screening and laser treatment, as shown in Table 2. Screening and treatment costs were collected from the Affiliated hospital of Weifang Medical University. AI software fee was obtained from the market quotation of the AI software supplier.

Costs
Costs were estimated from the health system perspective and societal perspective. Costs were collected in Chinese Yuan and then converted into US dollars at an exchange rate of 6.9129 yuan per dollar in 2020, as shown in Table 2.

From the societal perspective, the costs included direct costs (medical and nonmedical) and indirect costs

Table 2 Health system and Societal Costs Per Person for DR Screening and Treatment in US Dollars

| Cost Items                      | Cost ($)   | Sensitivity Analysis Range |
|---------------------------------|------------|---------------------------|
| **Health System costs**         |            |                           |
| 1. Screening                    |            |                           |
| AI software                     | 1.447      | 0.723–2.17                |
| Ophthalmologist salary          | 3.213      | 1.606–4.819               |
| Eye examination                 | 1.63       | 0.815–2.445               |
| 2. Follow-up visit              |            |                           |
| Follow-up examination           | 2.199      | 1.099–3.298               |
| 3. Laser treatment              | 347.177    | 173.589–520.766           |
| **Societal costs**              |            |                           |
| 1. Income loss                  |            |                           |
| Blindness (for the first year)  | 8,920      | 4,460–13,380              |
| Blindness (in the following years) | 3,600  | 1,800–5,400               |
| Screening                       | 3.18       | 1.59–4.77                 |
| Treatment                       | 12.7       | 6.35–19.05                |
| 2. Transportation              |            |                           |
| Screening                       | 0.58       | 0.29–0.87                 |
| Follow-up visit                 | 2.30       | 1.15–3.45                 |

AI screening costs include cost of AI software and eye examination while ophthalmologist screening costs include salaries of ophthalmologist and eye examination. The costs of AI screening group’s follow-up visit include cost of AI software and follow-up examination. The costs of ophthalmologist screening group’s follow-up visit include cost of ophthalmologist salaries and follow-up examination.
(i.e., work time lost). We estimated health system cost of only direct medical costs. Direct medical costs can be divided into three parts: (1) costs of screening, (2) costs of follow-up examinations, (3) costs of laser treatment. For AI screening, the costs of screening included AI software fee, salaries of eye care professionals, maintenance of equipment, advertising and building rent. For ophthalmologist screening, the costs of screening included salaries of eye care professionals, maintenance of equipment, advertising, building rent, as well as salaries of ophthalmologists. Direct nonmedical costs consisted of transportation fees related to visits to the community hospitals and superior hospitals. Indirect costs consisted of the monetary value of work time lost, which was spent on screening, follow-up examinations and laser treatment. The costs caused by blindness were derived from a study by Tang et al. [34], which consisted of 53.2% direct medical costs, 6.4% direct nonmedical costs, and 40.4% indirect costs. Indirect costs included loss of labour resources, loss of productivity among caregivers and modification costs. The total cost for the first year of blindness was $8,920 and only indirect costs (i.e., $3,600)

![Cost-effectiveness curve showing dominated strategies and undominated strategies under the health system perspective](image_url)

**Fig. 2** Cost-effectiveness curve showing dominated strategies and undominated strategies under the health system perspective

| Table 3 | Cost-effectiveness results from the health system and societal perspectives |
|---------|-------------------------------------------------------------------------|
|         | Cost ($) | Incremental Cost (Δ$) | Effectiveness (QALYs) | Incremental Effectiveness (Δ QALY) | ICER (Δ$/Δ QALY) |
| 1. Health system perspective | | | | | |
| No screening | 0 | - | 16.59 | - | - |
| AI screening | 180.19 | 180.19 | 16.76 | 0.16 | 1,107.63 |
| Ophthalmologist screening | 215.05 | 34.86 | 16.71 | -0.04 | Dominated |
| 2. Societal perspective | | | | | |
| No screening | 0 | - | 16.59 | - | - |
| AI screening | 1,683.23 | 1,683.23 | 16.76 | 0.16 | 10,347.12 |
| Ophthalmologist screening | 1,775.48 | 92.25 | 16.71 | -0.04 | Dominated |

QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio
are incurred in subsequent years until death. Costs were discounted at an annual rate of 3%.

Effectiveness
Effectiveness was measured with quality-adjusted life years (QALYs) gained. Utility weights of different DR states were obtained from the published literature, using time trade-off method [30]. The QALYs were calculated by multiplying the utility values and the time spend in this health state [36]. The QALYs were also discounted at an annual rate of 3%.

Cost-effectiveness analysis
We analyzed the cost-effectiveness of the two screening strategies by using the Markov model. If the cost of AI screening was less expensive but provided more effectiveness than ophthalmologist screening, the ophthalmologist screening was dominated. Compared with no screening, we estimated the ICER of AI screening as the difference between the costs divided by the difference between the total QALYs gained. We determined whether AI screening was cost-effective by comparing the ICER with the threshold suggested by World Health Organization, 1–3 times the per capita gross domestic product (GDP), which was considered cost-effective [37]. The per capita GDP of China in 2019 was $10,255.03.

Sensitivity analysis
We performed a one-way sensitivity analysis in which parameters varied once at a time over the estimated ranges presented, to evaluate the impact of the uncertainty of some key model parameters on ICER. The minimum and maximum values were estimated from 95% confidence intervals for mortality multipliers, transition probabilities, utility values. For costs, a range of ±50% was applied. The discount rate range we used was recommended by WHO, 0%-6% [38]. Additionally, we performed a probabilistic sensitivity analysis in which variables varied simultaneously. It took repeated 10,000 samples across the ranges of the parameters. The results were presented graphically as cost-effectiveness curve, which was used to show the proportion of iterations in which AI screening was cost-effective at different willingness-to-pay thresholds.

Results
Cost-effectiveness analysis
The model estimated the cost and health outcomes of the two screening groups. The cost-effectiveness results, from the health system perspective in the 35 cycles, are shown in Fig. 2 and Table 3. Relative to no screening, AI screening was more expensive with an incremental cost of
$180.19, but more effective with an incremental QALYs of 0.16. The ophthalmologist screening was more expensive (incremental costs of $34.86) and less effective (incremental QALYs of -0.04) compared with the AI screening. The ICER of AI screening compared with no screening group was $1,107.63/QALY gained, less than the threshold of $30,765.09, which was three times Chinese per capita GDP in 2019. AI screening was considered cost-effective. Figure 2 showed that the ophthalmologist screening group was dominated by AI screening.

The ophthalmologist screening was still dominated by AI screening, from the societal perspective, as shown in Fig. 3 and Table 3. AI screening costs less than ophthalmologist screening ($1,683.23 versus $1,775.48). Relative to no screening, the ICER of AI screening was $10,347.12, below the cost-effective threshold ($10,255.03-$30,765.09). The ophthalmologist screening was more expensive (incremental costs of $92.25) and less effective (incremental QALYs of -0.04) compared with the AI screening. So AI screening was more cost-effective compared with ophthalmologist screening from both health system perspective and societal perspective.

**Sensitivity analysis**

**One-way sensitivity analysis**

The results of the one-way sensitivity analysis in the Tornado diagram from the health system perspective and societal perspective are shown in Fig. 4 and Fig. 5. The one-way sensitivity analyses revealed the effect which the model variables had on the results when other model variables remained unchanged. From the health system perspective, the most influential parameter was the utility of NO DR, followed by the costs of ophthalmologist salaries. From the societal perspective, the most influential parameter was still the utility of NO DR, followed by the costs of follow-up visit of ophthalmologist screening.

**Probabilistic sensitivity analysis**

The cost-effectiveness acceptability curve from the probabilistic sensitivity analysis (PSA) under the health system perspective was shown in Fig. 6. The ophthalmologist screening was considered cost-effective in 0 iterations at any given willingness-to-pay value. It showed AI screening was cost-effective versus no screening and ophthalmologist screening in 100% of the iterations at.
the willingness-to-pay threshold of $30,765.09/QALY, 3 times Chinese per capita GDP in 2019, under the health system perspective. The mean costs of non-dominated strategies, no screening and AI screening, were $0 and $180.19, respectively. The mean QALY of no screening was 16.59 QALYs and that of AI screening was 16.76 QALYs. The PSA results showed that the ICER between non-dominated strategies would be $1,107.63/QALY gained, which was below the threshold.

From the societal perspective, the ophthalmologist screening was considered cost-effective in 0 iterations at any given willingness-to-pay value as shown in Fig. 7. It showed AI screening was more cost-effective compared with no screening and ophthalmologist screening in 100% of the iterations at the willingness-to-pay threshold. The mean costs for AI screening and ophthalmologist screening were $1,683.23 and $1,775.48 respectively. The mean QALY of ophthalmologist screening was 16.71 QALYs and that of AI screening was 16.76 QALYs. Compared with no screening group, the ICER of AI screening, the dominant strategy, was $10,347.12, below the cost-effective threshold.

**Discussion**

This model-based economic evaluation compared two DR screening strategies from the health system perspective and societal perspective. The results suggested that AI screening would be the most cost-effective compared with no screening and ophthalmologist screening based on the threshold, 1–3 times per capita GDP of Chinese in 2019. Base-case results indicated that AI screening generated a cost saving of $34.86 while generating more QALYs (incremental QALYs of 0.04) relative to ophthalmologist screening from the health system perspective. From the societal perspective, AI screening generated a cost saving of $92.25. Promotion across the country can save labor costs and resources, as well as reduce the occurrence of DR. Our results suggested that the adoption of AI screening at the community health service stations was economically sound.

The lower cost of AI screening relative to ophthalmologist screening is attributed to the difference in the cost of grading fundus images. In our study, the costs of AI screening and ophthalmologist screening were basically the same except for the costs of grading. It costs less to grade a fundus image by AI screening relative to ophthalmologist screening ($1.447 per patient versus $3.213 per patient).
per patient). This is the main reason causing the difference between the cost-effectiveness of the two screening strategies.

Our results consist with the findings in previous literatures although the research settings are different [39–42]. The study of Tufail et al. reported the cost saving to be 12% to 21% for DR screening in the United Kingdom using ML (an AI-based technology) in comparison with human assessors [39]. A Scottish study showed a 46.7% cost-reduction by replacing first-level human assessment with automated grading in a national DR screening program [40]. The study by Xie et al. from Singapore reported fully automated DLS (deep learning systems) had a cost savings of 14.3% compared with human assessment system [41]. The study of Fuller et al. reported the primary care-based ARIAS screening among low-income patients with diabetes is substantially less costly [42].

Our study applied a more comprehensive system of prognosis after people were diagnosed with diabetes, based on Markov model. In our study, health states included DR states, blindness, death and the stable state after laser treatment, which reflect the natural progression of DR. We took more factors into consideration in our cost estimation. We calculate age-dependent mortality by using linear interpolation in order to obtain an accurate outcome.

We also perform a one-way sensitivity analysis and probabilistic sensitivity analysis to assess the uncertainty of cost and effectiveness. In our study, the results of cost-effectiveness analysis from two perspectives helped to provide more convincing and well-rounded evidence about the cost-effectiveness of AI based DR screening for the decision-making agency.

**Study limitations**

First, the transition probabilities and the utility values were partly derived from the results in other countries, which might be not exactly consistent with those in China, resulting in potential uncertainty in our study. We think the data we used were best available for our analysis. Second, we assumed that the patients’ compliance in AI screening and ophthalmologist screening were the same. Actually, as a cost- and time-saving strategy, AI screening is supposed to be more acceptable compared with ophthalmologist screening. Moreover, we assumed the compliance of follow-up examination and laser treatment were 100% to simplify the calculation. Third, we didn’t consider the rate of fundus images that could not be graded accurately, and just from one study to
determine the sensitivity and specificity of the AI screening. Fourth, in our study, we compared the ICER with the per capita GDP of the whole country instead of rural China. Fifth, we assumed all patients with newly diagnosed diabetes had no DR. In fact, some patients have a relative long duration of diabetes before definite diagnosis were established and early-stage diabetic retinopathy might occur.

Our analysis highlights the great need for further research in the areas of AI screening for DR. The distribution of different DR stages in rural China as well as DR progression rates between different stages should be surveyed analyzed. Additionally, the data on detailed costs for AI screening conducted in rural China, especially indirect costs (i.e., the income loss of patients’ family associated with their blindness) and the compliance of screening and follow-up examination should be investigated. Moreover, screening intervals have been found to have influence on cost-effectiveness in many countries [43–47]. Since we used screening intervals recommended by ICO guidelines for diabetic eye care, individualized screening intervals suitable for Chinese patients should be investigated.

To the best of our knowledge, this is the first economic evaluation of AI-based screening for DR in rural China. The results that AI screening is cost-effective compared with conventional screening indicate that AI might be a promising strategy in the future. Considering the lack of medical resource and high incidence of DR in rural area of China, we think that wide application of AI screening might improve the current situation. The findings by Lian et al. showed that free DR screening was more cost-effective for a healthcare provider than paying screening. Charging a small co-payment will decrease the willingness of the potential DR patients to participate in screening, especially the low-income subjects [48]. Due to the large amount of the population in the rural China and limited healthcare budget, free DR screening is not a practical and feasible approach at present. With the rapid development in AI technology, the cost of AI-based DR screening is expected to decrease dramatically and the performance will be further improved. Additionally, the AI screening will greatly alleviate the issue of ophthalmologists’ shortage in rural China. Meanwhile, since many oversea countries are faced with similar problems, such as lack of medical facilities, expensive manual screening costs and limited access to conventional screening programs for DR screening, AI screening for diabetic retinopathy may also be a feasible solution.
Conclusions
The results of our study show that AI screening saves costs in comparison with ophthalmologist screening for DR, which provide evidence for extending the application of AI-based DR screening across rural China.

Abbreviations
DR: Diabetic retinopathy; AI: Artificial intelligence; ICER: Incremental cost-effectiveness ratio; QALYs: Quality-adjusted life years; GDP: Gross domestic product; DLS: Deep learning systems; VITDR: Vision-threatening diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; PSA: Probabilistic sensitivity analysis.

Acknowledgements
We thank the Affiliated hospital of Weifang Medical University workers for providing data.

Authors' contributions
HP conceived the economic evaluation study. XH and BY designed the study and collected the data. XH, BY, WZ, QL, FX, PO and ML conducted and ran the trial. XL, JM, YC and HP analyzed the data and interpreted the economic evaluation findings. XH and BY drafted the manuscript. TZ and HP revised the manuscript. All authors read and approved the final manuscript.

Funding
This study is supported by Guangdong Medical Research Fund (A2019158), National College Students Innovation and Entrepreneurship Training Program (S2020105S9065).

Availability of data and materials
The datasets generated or analyzed during the current study are not publicly available due to privacy restrictions but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Jinan University (No. 2021–005) and performed in accordance with the Declaration of Helsinki. All subjects were aware of the research program and we have obtained their written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Ophthalmology, the First Affiliated Hospital, Jinan University, Guangzhou, China. 2. Institute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China. 3. Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China. 4. Department of Ophthalmology, Affiliated Hospital of Weifang Medical University, Weifang, China. 5. College of Pharmacy, Jinan University, Guangzhou, China. 6. School of Basic Medical Sciences, The Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. 7. Department of Histology and Embryology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.

Received: 18 February 2021 Accepted: 16 February 2022 Published online: 25 February 2022

References
1. Kashim RM, Newton P, Ojo O. Diabetic Retinopathy Screening a Systematic Review on Patients’ Non-Attendance. Int J Environ Res Public Health. 2018;15(1):157.
2. Feldman-Billard S, Langer E, Massin P. Stand Screening Surveillance O Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44(1):4–14.
3. Platania CBM, Maisto R, Trotta MC, D’Amico M, Rossi S, Gesualdo C, et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br J Pharmacol. 2019;176(13):2179–94.
4. Flasman SR, Boume RRA, Resnikoff S, Ardland B, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Global Health. 2017;5(12):E1221–34.
5. Yao J, Roger S, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35(3):S56–64.
6. Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Experiment Ophthalmol. 2016;44(4):260–77.
7. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.
8. P S, J Y, KY C, E T, health RIJJog. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. 2018;8(1):010803.
9. Lin KY, Hsh WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diab Investigation.
10. Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica. 2020;243(1):9–20.
11. Rajalakshmi R, Prathiba V, Arulmalar S, Usha M. Review of retinal cameras for global coverage of diabetic retinopathy screening. Eye. 2021;35(1):162–72.
12. Xie YC, Nguyen QD, Hamzah H, Lim G, Bellamo V, Gunasekeran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.
13. Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA. 2017;318(22):2211–23.
14. Dismuke C. Progress in examining cost-effectiveness of AI in diabetic retinopathy screening. Lancet Digital Health. 2020;2(5):E212–3.
15. He J, Cao TY, Xu FP, Wang SS, Tao HQ, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye. 2020;34(3):572–6.
16. Li ZX, Zhang J, Feng N, He MG. Using artificial intelligence as an initial triage strategy in diabetic retinopathy screening program in China. Zhonghua Yi Xue Za Zhi. 2020;100(48):3835–40.
17. Ming S, Xie K, Lei X, Yang Y, Zhao Z, Li S, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
18. Shah A, Clarida W, Amelon R, Hernandez-Ortega MC, Navea A, Morales-Olivas J, et al. Validation of Automated Screening for Referable Diabetic Retinopathy With an Autonomous Diagnostic Artificial Intelligence System in a Spanish Population. J Diabetes Sci Technol. 2021;15(3):655–63.
19. Bhaskaranand M, Ramachandra C, Bhat S, Cuadros J, Nittala MG, Sadda SR, et al. The Value of Automated Diabetic Retinopathy Screening with the EyeArt System. A Study of More Than 100,000 Consecutive Encounters from People with Diabetes. Diabetes Technol Ther. 2019;21(11):E353–43.
20. Ming S, Xie KP, Lei X, Wang YR, Zhao ZX, Li SY, et al. Evaluation of a novel artificial intelligence-based screening system for diabetic retinopathy in community of China: a real-world study. Int Ophthalmol. 2021;41(4):1291–9.
21. Li YZ, Teng D, Shi XG, Qin GJ, Qin YF, Quan HB, Prevalence of diabetes recorded in mainland China using, et al. diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ Brit Med J. 2018;2020:369.

22. Wong TY, Sun J, Kawasaki R, Ramuvinboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608–22.

23. He J, Cao T, Xu F, Wang S, Tao H, Wu T, et al. Artificial intelligence-based screening for diabetic retinopathy at community hospital. Eye (Lond). 2020;34(3):572–6.

24. Li M, Wang GY, Xia HH, Tang XY, Feng ZQ, et al. Clinical evaluation of artificial intelligence system based on fondus photograph in diabetic retinopathy screening. Chin J Exp Ophthalmol. 2019;37(8):663–8.

25. Khalaf SS, Al‑Bdour MD, Al‑Till MI. Clinical biomicroscopy versus flou‑rescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy. Eur J Ophthalmol. 2007;17(1):84–8.

26. Zhang WJ, Wei M. The evaluation of the mortality and life expectancy of chinese population. Population Journal. 2016;38(03):18–28.

27. Tung TH, Chen SJ, Shih HC, Chou P, Li AF, Lee FL, et al. Assessing the natu‑ral course of diabetic retinopathy: A population-based study in Kinmen. Taiwan Ophthalmic Epidemiology. 2006;13(3):327–33.

28. Javitt JC, Aiello LP, O’JX, McGhee SM, Gangwani RA, Chan CKW, Lam CLK, Yap MKH, et al. Artificial intelligence for teleophthalmology‑based diabetic retinopathy screening in a national programme: an economic analysis modelling the impact of related comor‑bidities/complications. Eur J Health Economics. 2020;21(7):729–43.

29. Tang J, Liang Y, O’Neill C, Kee F, Jiang J, Congdon N. Cost-effectiveness and cost‑utility of population-based glaucoma screening in China: a decision‑analytic Markov model. Lancet Glob Health. 2019;7(7):e968–78.

30. Yiangopoulos J, Chantzara A. Health‑related quality of life and health utilities in insulin‑treated type 2 diabetes: the impact of related comor‑bidities. J Diabetes Sci Technol. 2020:1932296820967011.

31. Smith DH, Johnson ES, Russell A, Hazlehurst B, Muraki C, Nichols GA, et al. Lower visual acuity predicts worse utility values among patients with type 2 diabetes. Quality of life research : an international journal of quality‑of‑life studies. 2008;17(10):1277–84.

32. Singal AK, Nebiker RM, Bredenberg CE, Weinreb RN. Individualised variable ‑interval risk‑based screening for sight‑threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia. 2017;60(11):2174–82.

33. Scotland G, McKiegupe P, Seleep J, Leal Jr, Oke J, Siva Prasad S, et al. Development of a cost‑effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015;19(74):1.

34. Zhao Q, Wang L, Tao T, Xu B. The cost‑effectiveness analysis / edited by T. Tan‑Torres Edejer ... [et al]. Geneva: World Health Organization, 2003.

35. Hutubessy R, Chisholm D, Edeser TT. Generalized cost‑effectiveness analysis for national‑level priority‑setting in the health sector. Cost effec‑tiveness and resource allocation: C/E. 2003;11(8).

36. World Health Organization. Tofitilumab RMPH, Adam T, Tan‑Torres Edejer T, Hutubessy R, Acharya A, et al. Making choices in health: WHO guide to cost‑effectiveness analysis / edited by T. Tan‑Torres Edejer ... [et al]. Geneva: World Health Organization, 2003.

37. Tuval A, Rudisill C, Egan C, Kapetanakis V, Salas‑Vega S, Owen C, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost‑Effectiveness Compared with Human Graders. Ophthalmology. 2017;124(3):343–51.

38. Scotland G, McNamee P, Philip S, Fleming A, Goatman K, Prescott G, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. BMJ Ophthalmol. 2007;91(11):1518–23.

39. Xie X, Nguyen QD, Hanhaz H, Lim G, Bellomo V, Gunasekaran DV, et al. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. Lancet Digital Health. 2020;2(5):E240–9.

40. Fuller SD, Hu J, Liu JC, Gibson E, Gregory M, Kuo J, et al. Five‑Year Cost‑Effectiveness Modeling of Primary Care‑Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low‑Income Patients with Diabetes. J Diabet Sci Technol. 2020;19:3296820967011.

41. Thomas RL, Winfield TG, Prettyjohns M, Dunstan FD, Cheung WY, Anderson PM, et al. Cost‑effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. Eur J Health Econ. 2020;21(7):993–1002.

42. Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, et al. Frequency of Evidence‑Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017;376(16):1507–16.

43. Eleuteri A, Fisher AC, Broadbent DM, Garcia‑Finana M, Cheyne CP, Wang A, et al. Individualised variable‑interval risk‑based screening for sight‑threatening diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia. 2017;60(11):2174–82.